Navigation Links
VirtualScopics Receives Issuance of Influential Patent in Canada
Date:9/18/2012

ROCHESTER, N.Y., Sept. 18, 2012 /PRNewswire/ -- VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of quantitative imaging solutions, announced today that its patent titled Automated Measurement of Anatomical Structures in Medical Imaging recently received issuance in Canada.  This is the 18th patent awarded to VirtualScopics worldwide for its algorithms and processes supporting quantitative medical imaging analysis. The company holds 10 patents within the United States.

VirtualScopics' Chief Scientific Officer, Dr. Edward Ashton stated, "We are pleased that Canada has issued this important patent recognizing VirtualScopics' innovative science and research." He added, "The research behind this patent led us to the creation of a system and method to fully automate the measurement of anatomical structures from medical images. The accurate identification and measurement of various anatomical structures is a vital tool for the evaluation of disease progression and patient response to therapy for numerous diseases." He continued, "This system for automated measurements continues to distinguish VirtualScopics among imaging providers who assist the leading pharmaceutical and medical device companies in the development of their drugs, devices and biologics." He concluded, "These systems and methods will also be the key drivers in the development of our personalized medicine applications."

About VirtualScopics, Inc.VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development.  VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images.  In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster.  For more information about VirtualScopics, visit www.virtualscopics.com.

Forward-Looking StatementsThe statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company's investment in infrastructure and new customer contract signings and awards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.  Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2011 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at www.sec.gov. These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to contact awards, the risk that they may not get signed.  Other risks include the company's dependence on its largest customers and risks of contract performance, protection of our intellectual property and the risks of infringement of the intellectual property rights of others. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.

 CONTACT: Investor Relations:Company Contact:Tim Ryan

Molly HendersonThe Shoreham Group

Chief Business and Financial Officer80 Eighth Ave, Ste 1107

500 Linden OaksNew York, NY 10011

Rochester, New York 14625+1 212 242 7777 Direct

+1 585 249.6231tryan@shorehamgroupllc.com 
'/>"/>

SOURCE VirtualScopics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. VirtualScopics to Present at the Upcoming Rodman & Renshaw Annual Global Investment Conference
2. VirtualScopics Announces Receipt of Notice from Nasdaq
3. VirtualScopics Reports 2nd Quarter 2012 Results
4. VirtualScopics Schedules Second Quarter 2012 Earnings Announcement
5. Lifeline Biotechnologies Receives Third Software Patent
6. Dehaier Medical Receives SFDA Approval for DHR-CPAP-C5
7. TechPrecision Receives Additional Medical Purchase Orders Exceeding $1.5 Million
8. Sinovac Receives Beijing CDC Tender Award to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
9. NeuroSigma Receives CE Certification
10. Surefire Medicals Infusion System For Embolization Procedures Receives CE Mark Approval
11. Roche receives FDA clearance for herpes simplex virus type 1 and 2 tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... 2017  The global market for liquid biopsy diagnostic ... million in 2016.  Although in early stages, the global ... particular as a result of the gradual shift towards ... introduction of a significant number of new liquid biopsy ... tumor biomarkers to guide treatment decisions. ...
(Date:7/10/2017)... , July 10, 2017 The Institute for ... methods, is the recipient of a VITROCELL® inhalation exposure ... International Science Consortium. The device, which is designed to ... expose human lung cells to airborne test materials in ... use the VITROCELL® system for testing combustible tobacco products, ...
(Date:7/5/2017)... , July 5, 2017 Wolfmet 3D  printed ... as physics and manufacturing combine to progress molecular radiotherapy imaging. ... SPECT systems are unable to accurately quantify the radiation absorbed ... information regarding the success of this radiotherapy treatment has been ... ...
Breaking Medicine Technology:
(Date:7/24/2017)... Cambridge, MA (PRWEB) , ... July 24, 2017 , ... ... for an invigorating and educational conference, InstructureCon. Each annual event is coupled with a ... next level with a James Bond theme, Mission: InstructureCon 0017. , To extend ...
(Date:7/24/2017)... ... July 24, 2017 , ... Puregraft, the ... announces the issuance of United States Patent Number 9,695,398 (the '398 patent) and ... The '398 and '324 patents cover methods and systems for optimizing fat ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... Paul Vitenas, ... the nation’s top level plastic surgeons, invited to attend Allergan’s recent meeting with their ... most valued companies in the world, Allergan is bringing a newly defined structure to ...
(Date:7/24/2017)... VA (PRWEB) , ... July 24, 2017 , ... ... Managers, **Presented by FDAnews and MSceppa Consulting **, Aug. 22-23, 2017 – Arlington, ... on Friday, July 28. , Increased FDA scrutiny and growing demands to track ...
(Date:7/24/2017)... ... ... “Nana Nana Boo Boo”: a delightful tale of a young girl who ... Boo” is the creation of published author Michael Rush, a Deputy Sheriff, former world ... Rush’s new book presents the importance of manners in a way easily understood by ...
Breaking Medicine News(10 mins):